Key facts
- This page summarizes Clay Thorp's Form 4 filing for PhaseBio Pharmaceuticals Inc.
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 19 May 2023, 16:18.
Clay Thorp - 19 May 2023 Form 4 Insider Report for PhaseBio Pharmaceuticals Inc
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 19 May 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 19 May 2023, 16:18:34 UTC
- Prior SEC filing
- 21 Dec 2022
- Next SEC filing
- 23 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan P. Mow, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Clay Thorp filed Form 4 for PhaseBio Pharmaceuticals Inc on 19 May 2023.
Change
- Previous filing in this sequence was filed on 21 Dec 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PHASQ
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +3,750
- Change %
- +11%
- Price
- Shares after
- 36,693
- Date
- 19 May 2023
- Ownership
- Direct
- Footnotes
- F1
PHASQ
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,545,040
- Date
- 19 May 2023
- Ownership
- See footnote
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PHASQ
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- +3,750
- Change %
- Price
- $0.000000*
- Shares after
- 0
- Date
- 19 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,750
- Exercise price
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock.
Footnote F2
The Reporting Person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of Hatteras Venture Partners IV, LP ("HVP IV") and Hatteras NC Fund, LP ("Hatteras NC"). HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC.
Footnote F3
The Reporting Person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
Footnote F4
The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date.